Status:
COMPLETED
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
Lead Sponsor:
Shire
Conditions:
Essential Thrombocythemia (ET)
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to provide SPD422 to subjects who completed Study SPD422 308 and, in the opinion of the Investigator, will continue to benefit from treatment.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects must have completed Study SPD422 308
Exclusion
Key Trial Info
Start Date :
October 27 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT01467661
Start Date
October 27 2010
End Date
May 1 2015
Last Update
June 9 2021
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Akita University Hospital
Akita, Akita, Japan, 010-8543
2
Tokyo Metropolitan Cancer and Infectious diseases Center Kom
Honkomagome 3-18-22, Bunkyo-ku, Japan, 13 113-8677
3
Nippon Medical School Hospital
Sendagi 1-1-5, Bunkyo-ku, Japan, 13 113-8603
4
Chiba University Hospital
Chuo-ku Inohana 1-8-1, Chiba-shi, Japan, 12 260-8677